Though news of handful of corporate deals pushed stocks higher early Monday, the markets closed slightly lower after to Secretary of State Kerry boosted the pressure on Syria.
Microsoft starts the second of two landmark trials with a unit of Google over patent rights for certain smartphone and Internet technologies.
AstraZeneca takes another step to bolster its pipeline of new cancer drugs by agreeing to acquire biotech company Amplimmune for up to $500 million.
Amgen is close to buying Onyx Pharmaceuticals $125 a share, or more than $10 billion, in a deal that is expected to be announced as soon as Monday, sources say.
Medical Marijuana is now legal in 20 states, and there are some legitimate ways to invest in it. But there are also some sketchy investment schemes to watch out for.
Yum Brands and its KFC unit continue to struggle in China, as a key measure of Yum's sales tumbled 13 percent last month, far worse than expected.
Drug-giants Merck and Pfizer beat earnings estimates, as patent expirations on key drugs loom.
Pfizer reports better-than-expected earnings as the drugmaker lines up a business split that could lead to the spin-off of its generics division.
Apple files an application in Japan to get a trademark on the name "iWatch," fueling rumors that the company is getting ready to roll out a new device.
Chinese factory workers release their U.S. boss, held captive for a week, after a compensation dispute is resolved.
The equity market got off to a hot start but quickly lost its footing. All three indexes closed lower, with trading more volatile than it's been in months.
With the ongoing decriminalization of pot come new -- and legal -- ways to invest in the marijuana business. But before you do, there are a few things you need to know.
A split decision on Wall Street, and a big sell-off for biotech stocks. Some of the biggest Nasdaq stocks, and best performers this year, gave back some of their recent gains.
The maker of Welbutrin will pay nearly $9 billion for Bausch & Lomb, which makes eye-care products.
A federal judge Friday declined to temporarily halt a court order directing the FDA to make emergency contraception available over-the-counter to girls of all ages.
Spending on prescription medicines in the U.S. fell for the first time in decades last year, as cash-strapped consumers continued to cut back on use of health-care services.
The Dow Industrials closed yesterday above the 15,000 level for the first time. It's the Dow's 16th record this year. The S&P 500 also set another record.
BP is set to jump after earnings blew past expectations. The company has also been hit by 2200 new lawsuits in recent weeks, as a deadline for new oil spill claims nears.
Pfizer reported lower-than-expected quarterly earnings and revenue and the largest U.S. drugmaker trimmed its full-year profit outlook.
Bayer has agreed to buy U.S. contraceptive devices maker Conceptus for $1.1 billion, aiming to underpin its position as the world's largest women's healthcare provider.
Bristol-Myers Squibb posted a 45 percent drop in first-quarter profit as revenue from its Plavix blood-thinning drug plunged 95%.
Regulators said yesterday that generic drugmakers would not be licensed to make cheap versions of Purdue Pharma's OxyContin, a powerful and widely abused narcotic.
Eli Lilly plans to cut hundreds of workers from its U.S. sales force as the drugmaker prepares to deal with the loss of patent protection for two more top-selling drugs.